Showing 1 - 10 of 468
. Here we explore the importance within the biotechnology industry of the non-financial metrics firms used to convey value … was a change over time in the importance of various metrics in determining the value of a biotechnology firm. We find that … value. Our results also suggest that the biotechnology regime changed and the Nobel Prize lost its luster as a signal of …
Persistent link: https://www.econbiz.de/10012464045
North American Industry Classification System (NAICS) as biotechnology firms to estimate several Fama-French three factor …In the current study we find that biotechnology firms are exposed to greater financial risk than other industries and … capital over the 1982-2005 time period were 16.25 percent for biotechnology firms. Of course, these average estimates obscure …
Persistent link: https://www.econbiz.de/10012465042
Using data on over 900 firms for the period 1988-2000, we estimate the effect on phase-specific biotech and pharmaceutical R&D success rates of a firm's overall experience, its experience in the relevant therapeutic category; the diversification of its experience, and alliances with large and...
Persistent link: https://www.econbiz.de/10012469083
Scientist-entrepreneurs prominent in biotech and other high-technology industries view going public not as a cost-effective source of capital but as a cross between selling a now-proven innovation and winning a lottery. Unlike most empirical IPO analyses confined to those firms that go public,...
Persistent link: https://www.econbiz.de/10012469760
Commercializing knowledge involves transfer from discovering scientists to those who will develop it commercially. New codes and formulae describing discoveries develop slowly - with little incentive if value is low and many competing opportunities if high. Hence new knowledge remains naturally...
Persistent link: https://www.econbiz.de/10012470219
, such as intellectual human capital, can predict where and when biotechnology enterprises emerge and agglomerate. Density … more conjectural than empirically tenable. We argue and demonstrate for biotechnology that an alternative model based on … essentially uncorrelated with the panel data on biotechnology entry by year and region while the combined model has correlation …
Persistent link: https://www.econbiz.de/10012472394
In this paper, we examine the determinants of control rights in technology strategic alliances between biotechnology … firms and pharmaceutical corporations, as well as with other biotechnology firms. We undertake three clinical studies and an …
Persistent link: https://www.econbiz.de/10012472804
.S. biotechnology enterprises during 1976-1989. Using a linked cross-section/time- series panel data set, we find that the timing and … structures. We believe biotechnology may be prototypical of the birth patterns in other innovative industries …
Persistent link: https://www.econbiz.de/10012474283
We evaluate the effects of state-provided financial incentives for biotech companies, which are part of a growing trend of placed-based policies designed to spur innovation clusters. We estimate that the adoption of subsidies for biotech employers by a state raises the number of star biotech...
Persistent link: https://www.econbiz.de/10012459367
Recent policy attention has focused on proposals to reduce prices for drugs that have received public funding. From an implementation perspective, such policies rely on public disclosure of government support for research. In this paper, we highlight two conceptual problems with past attempts to...
Persistent link: https://www.econbiz.de/10012482567